| KEDRION |
KEDRION |
92%
|
Sales to Kedrion accounted for approximately 30%, 31% and 23% of our total revenues in the years ended December 31, 2025, 2024 and 2023, respectively. |
| BAX |
Baxter International Inc. |
85%
|
Reciprocal relationship from BAX graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from BAX graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from BAX grap… |
| BAXALTA-US-INC |
BAXALTA-US-INC |
85%
|
er assigned all its rights under the collaboration agreement to Baxalta US Inc. (“Baxalta”) which was acquired during 2016 by Shire plc. (“Shire”), which is now part of Takeda (“Takeda” and in these … |
| BAXTER-HEALTHCARE-CORPORATION |
BAXTER-HEALTHCARE-CORPORATION |
85%
|
2010, the Company entered into a 30 -year collaboration agreement with Baxter Healthcare Corporation (“Baxter”) with respect for granting of the distribution rights for GLASSIA. During 2015, Baxter a… |
| BIOTEST-AG |
BIOTEST-AG |
85%
|
/or at a reasonable cost, would have a material adverse effect on our business, financial condition and results of operations. Sales of products supplied by Biotest AG, Kedrion, Chiesi Farmaceutici S… |
| CSL-BEHRING-LTD |
CSL-BEHRING-LTD |
85%
|
as our future results of operations and profitability. CYTOGAM is manufactured at our facility in Beit Kama, Israel since 2023. To manufacture CYTOGAM, we engaged Prothya Biosolutions Belgium (“Proth… |
| KEDRION-KEDPLASMA-LLC |
KEDRION-KEDPLASMA-LLC |
85%
|
31, 2033. We currently also purchase from a subsidiary of Kedrion, KedPlasma LLC (“Kedplasma”), a large portion of the hyper-immune plasma, which is used for the production of KEDRAB/KAMRAB. See “— W… |
| ALVO |
Alvotech |
72%
|
License Application (BLA) of the product, in consideration for a $ million payment from Takeda, which was paid by Takeda and accounted for as income during the first quarter of 2022. Commencing 2022,… |
| ALVO |
Alvotech |
72%
|
Reciprocal relationship from ALVO graph: Reciprocal relationship from KMDA graph: License Application (BLA) of the product, in consideration for a $ million payment from Takeda, which was paid by Tak… |
| NVSEF |
Novartis AG |
72%
|
sell products in the Distribution segment in Israel, we must register the products, at our own expense, with the IMOH. We cannot predict how long the registration process of the IMOH may take or whet… |
| NVSEF |
Novartis AG |
72%
|
Reciprocal relationship from NVSEF graph: Reciprocal relationship from KMDA graph: sell products in the Distribution segment in Israel, we must register the products, at our own expense, with the IMO… |
| SNYNF |
Sanofi |
72%
|
sell products in the Distribution segment in Israel, we must register the products, at our own expense, with the IMOH. We cannot predict how long the registration process of the IMOH may take or whet… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from SNYN… |
| VALN |
Valneva SE |
72%
|
tici S.p.A, Bio Products Laboratories (“BPL”) and Valneva SE, which are sold in our Distribution segment, together represented approximately 8%, 18% and 20% of our total revenues for the years ended … |
| VALN |
Valneva SE |
72%
|
Reciprocal relationship from VALN graph: Reciprocal relationship from KMDA graph: Reciprocal relationship from VALN graph: Reciprocal relationship from KMDA graph: tici S.p.A, Bio Products Laboratori… |
